Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells

KÜÇÜKTÜRKMEN B., BOZKIR A.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, cilt.44, sa.2, ss.306-315, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 2
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1080/03639045.2017.1391835
  • Dergi Adı: DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.306-315
  • Anahtar Kelimeler: Pemetrexed, anti-miRNA oligonucleotide, microRNA-21, solid lipid nanoparticles, glioblastoma, IN-VITRO CHARACTERIZATION, CENTRAL-NERVOUS-SYSTEM, BLOOD-BRAIN-BARRIER, DRUG-DELIVERY, VIVO, TEMOZOLOMIDE, FORMULATION, INHIBITION, RELEASE, TRANSPORT
  • Ankara Üniversitesi Adresli: Evet

Özet

The practical use of solid lipid nanoparticles (SLNs) in research has been highlighted in the literature, but few reports have combined SLNs with miRNA-based therapy and chemotherapy. We aimed to prepare cationic SLNs (cSLNs) to load anti-miR-21 oligonucleotide and pemetrexed for glioblastoma therapy in vitro. cSLNs were employed to encapsulate both pemetrexed and anti-miR-21 by a high-pressure homogenization method, and then the properties of cSLNs were characterized. We studied cellular uptake and cytotoxicity properties of cSLNs in U87MG cells. cSLNs were 124.9 +/- 1.6 nm in size and 27.3 +/- 1.6 mV in zeta potential with spherical morphology in the TEM image. cSLNs uptake by U87MG cells was increased significantly higher and more effective than free pemetrexed. These findings suggest that cSLNs represent a potential new approach for carrying both pemetrexed and anti-miR-21 for glioblastoma therapy.